Bionano Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>BG</div>
BNGO -- USA Stock  

USD 8.27  0.22  2.73%

Bionano Genomics Sales per Share is quite stable at the moment as compared to the past year. The company's current value of Sales per Share is estimated at 0.99. Tangible Assets Book Value per Share is expected to rise to 2.44 this year, although the value of Earnings Before Interest Taxes and Depreciation Amortization EBITDA will most likely fall to (28.5 M). The goal of this thesis is to give institutional investors our take on Bionano future value. We will inspect the reasons why it could be a game-changer for Bionano Genomics institutional investors.
Published over two weeks ago
View all stories for Bionano Genomics | View All Stories
Our latest forecast of Bionano (NASDAQ:BNGO)
Bionano Genomics is OVERVALUED at 1.71 per share with modest projections ahead. About 6.0% of Bionano Genomics shares are held by institutions such as insurance companies. Insiders ownership of Bionano Genomics refers to the amount of Bionano Genomics equity owned by Bionano officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Bionano, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Bionano Genomics. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Bionano Genomics

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Bionano Genomics' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Bionano Genomics in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Bionano Genomics. Your research has to be compared to or analyzed against Bionano Genomics' peers to derive any actionable benefits. When done correctly, Bionano Genomics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Bionano Genomics.

How important is Bionano Genomics's Liquidity

Bionano Genomics financial leverage refers to using borrowed capital as a funding source to finance Bionano Genomics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Bionano Genomics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Bionano Genomics's total debt and its cash.

How Bionano utilizes its cash?

To perform a cash flow analysis of Bionano Genomics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Bionano Genomics is receiving and how much cash it distributes out in a given period. The Bionano Genomics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Bionano Genomics Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (28.67 Million)

Acquisition by Chaubey Alka of 300000 shares of Bionano Genomics subject to Rule 16b-3

Legal trades by Bionano Genomics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Bionano insider trading alert for grant of stock option (right to buy) by Chaubey Alka, Chief Medical Officer, on 11th of October 2020. This event was filed by Bionano Genomics Inc with SEC on 2020-09-03. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Bionano Genomics Indicators

Bionano Genomics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Bionano Genomics independently to ensure intended market timing strategies are aligned with expectations about Bionano Genomics volatility.

Margin Breakdown

EBITDA Margin(2.81)
Gross Margin0.33
Profit Margin(3.18)

Our perspective of the latest Bionano Genomics rise

Bionano Genomics latest risk adjusted performance surges over 0.24. As of the 31st of December, Bionano Genomics shows the Risk Adjusted Performance of 0.2366, downside deviation of 3.64, and Mean Deviation of 5.68. Bionano Genomics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Bionano Genomics, which can be compared to its rivals. Please confirm Bionano Genomics coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Bionano Genomics is priced correctly, providing market reflects its regular price of 3.08 per share. Given that Bionano Genomics has jensen alpha of 2.56, we suggest you to validate Bionano Genomics's prevailing market performance to make sure the company can sustain itself at a future point.

Our Final Takeaway

Whereas some companies under the diagnostics & research industry are still a bit expensive, Bionano Genomics may offer a potential longer-term growth to institutional investors. To conclude, as of the 31st of December 2020, we believe Bionano Genomics is currently overvalued. It moves totally opposite to the market and projects quite high odds of financial distress in the next two years. Our present 30 days buy vs. sell advice on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Bionano Genomics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com